Skip to main content
DCTH
NASDAQ Industrial Applications And Services

Delcath Q3 Revenue Jumps 71% to $35.1M, 2026 Guidance Raised to $115M-$117M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$16.68
Mkt Cap
$518.053M
52W Low
$8.12
52W High
$17.42
52W Position info
105% above low
Off High info
4.2% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

DCTH has more than doubled off its 52-week low of $8.12.

Summary

Delcath reported Q3 revenue of $35.1 million (up 71% year over year) and net income of $7.0 million, then raised 2026 revenue guidance to $115 million-$117 million. Cash of $104.3 million and no debt mean the growth is self-funded.


Key Events · Earnings and Guidance · DCTH

  • Q3 Revenue Up 71% to $35.1M

    Total revenue of $35.1 million versus $20.6 million in Q3 2025, with HEPZATO KIT at $32.7 million and CHEMOSAT at $2.4 million.

  • Net Income $7.0M, EBITDA $11.5M

    Net income of $7.0 million versus $0.8 million a year ago; non-GAAP adjusted EBITDA of $11.5 million versus $5.3 million.

  • 2026 Guidance Raised to $115M-$117M

    Full-year revenue outlook lifted from the prior $104 million-$108 million range, reflecting at least 41% HEPZATO KIT volume growth over 2025.

  • Cash $104.3M, No Debt

    Cash and investments of $104.3 million as of September 30, 2026, with $8.2 million of cash provided by operations in the quarter.


Analysis · DCTH · Industrial Applications And Services

The raised guidance is the number that matters for whether the stock holds its 52-week high. Q3 revenue of $35.1 million rose 71% from $20.6 million a year ago, and net income of $7.0 million dwarfed last year's $0.8 million. Management lifted full-year 2026 revenue guidance to $115 million-$117 million from the prior $104 million-$108 million range, implying at least 41% HEPZATO volume growth. With $104.3 million in cash and no debt, the company is funding its own expansion and the DELUMA breast-cancer trial without dilution.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DCTH was trading at $16.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $518.1M. The 52-week trading range was $8.12 to $17.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DCTH - Latest Insights

DCTH
Nov 09, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $14.94
Real-time Price: $17.00 info
Change: +$2.06 (+14%) info
Market Cap: $518.053M info
DCTH
Aug 06, 2026, 9:09 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $14.00
Real-time Price: $17.00 info
Change: +$3.00 (+21%) info
Market Cap: $518.053M info
DCTH
Aug 06, 2026, 8:16 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $14.50
Real-time Price: $17.00 info
Change: +$2.50 (+17%) info
Market Cap: $518.053M info
DCTH
Aug 06, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.28
Real-time Price: $17.00 info
Change: +$2.71 (+19%) info
Market Cap: $518.053M info
DCTH
May 14, 2026, 8:23 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.32
Real-time Price: $17.00 info
Change: +$5.68 (+50%) info
Market Cap: $518.053M info